CLAIMS

1. A non-human animal model of Guillain-Barré syndrome which can be obtained by immunizing with gangliosides GQ1b a non-human animal whose FcγRIIB-gene function is deficient in its chromosome to develop Guillan-Barre syndrome.

2. A non-human animal model of Guillain-Barré syndrome, wherein Guillain-Barré syndrome is Fisher syndrome.

3. The non-human animal model of Guillain-Barré syndrome according to claim 1 or 2, which develops peripheral neuropathy wherein paralysis of its tail and hind legs occurs.

4. The non-human animal model of Guillain-Barré syndrome according to any one of claims 1 to 3, wherein the FcγRIIB-gene-deficient non-human animal is a rodent.

5. The non-human animal model of Guillain-Barré syndrome according to claim 5, wherein the rodent is a mouse.

6. A screening method of a therapeutic agent for Guillain-Barré syndrome wherein a test substance is administered to the non-human animal model of Guillain-Barré syndrome according to any one of claims 1 to 5, to observe and assess the degree of symptoms of Guillain-Barré syndrome in the non-human animal model of the syndrome.

7. A screening method of a therapeutic agent for

17

Guillain-Barré syndrome and/or Fisher syndrome wherein a test substance is administered to the non-human animal model of Guillain-Barré syndrome according to any one of claims 1 to 5, to measure and assess the level of anti-GQ1b antibody appearance.

8. A therapeutic agent that can be obtained by the screening method of a therapeutic agent for Guillain-Barré syndrome according to claim 6 or 7.